博瑞医药: 可转债转股结果暨股份变动公告

Core Viewpoint - The announcement provides an update on the conversion status of the "博瑞转债" (Bright Gene Convertible Bonds) and outlines the current state of the company's convertible bonds, including the amount converted and remaining unconverted bonds. Group 1: Convertible Bond Issuance Overview - The company issued 4.65 million convertible bonds with a total value of RMB 46.5 million on January 4, 2022, with a maturity period of six years starting from the issuance date [2]. - The bonds began trading on the Shanghai Stock Exchange on January 27, 2022, under the name "博瑞转债" and code "118004" [2]. Group 2: Conversion Status - As of March 31, 2025, RMB 100,000 worth of bonds had been converted into 2,870 shares, representing 0.0007% of the total shares before conversion [1][5]. - By the same date, a total of RMB 159,000 had been converted into 4,550 shares, which is 0.0011% of the total shares before conversion [1][5]. - The remaining unconverted amount of the convertible bonds is RMB 464,835,000, accounting for 99.9645% of the total issuance [1][5]. Group 3: Share Capital Changes - The total share capital before the conversion was 422,466,646 shares, which increased to 422,469,516 shares after the conversion of the bonds [5].